Schroder Investment Management Group
TERN

Schroder Investment Management Group’s Terns Pharmaceuticals TERN Stock Holding History

Schroder Investment Management Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-99,360
Closed -$4.03M – 1255
2025
Q4 		$4.03M Sell
99,360
-118,571
-54% -$2.74M ﹤0.01% 791
2025
Q3 		$1.7M Sell
217,931
-158,273
-42% -$1.01M ﹤0.01% 958
2025
Q2 		$1.4M Hold
376,204
– – ﹤0.01% 960
2025
Q1 		$1.1M Buy
376,204
+272,696
+263% +$1.11M ﹤0.01% 977
2024
Q4 		$572K Hold
103,508
– – ﹤0.01% 1085
2024
Q3 		$885K Sell
103,508
-151,176
-59% -$1.24M ﹤0.01% 1046
2024
Q2 		$1.73M Buy
+254,684
New +$1.54M ﹤0.01% 947

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Schroder Investment Management Group's TERN Position: Q1 2026 in Review

Schroder Investment Management Group sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 99,360 shares — an estimated $4.03M sold.

Schroder Investment Management Group first reported a position in TERN in Q2 2024 and held it in 7 quarters. The position peaked at $4.03M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Schroder Investment Management Group reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Schroder Investment Management Group sold 99,360 Terns Pharmaceuticals shares in Q1 2026, an estimated $4.03M.
  • Schroder Investment Management Group first reported a position in Terns Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • Schroder Investment Management Group's Terns Pharmaceuticals position peaked at $4.03M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.